Literature DB >> 16740370

Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence.

Keith G Heinzerling1, Steven Shoptaw, James A Peck, Xiaowei Yang, Juanmei Liu, John Roll, Walter Ling.   

Abstract

OBJECTIVE: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence.
METHODS: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples.
RESULTS: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use).
CONCLUSIONS: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740370     DOI: 10.1016/j.drugalcdep.2006.03.019

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  31 in total

Review 1.  Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

4.  A pilot trial of integrated behavioral activation and sexual risk reduction counseling for HIV-uninfected men who have sex with men abusing crystal methamphetamine.

Authors:  Matthew J Mimiaga; Sari L Reisner; David W Pantalone; Conall O'Cleirigh; Kenneth H Mayer; Steven A Safren
Journal:  AIDS Patient Care STDS       Date:  2012-10-03       Impact factor: 5.078

Review 5.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 6.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

7.  The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.

Authors:  Richard De La Garza; Todd Zorick; Keith G Heinzerling; Steve Nusinowitz; Edythe D London; Steven Shoptaw; David E Moody; Thomas F Newton
Journal:  Pharmacol Biochem Behav       Date:  2009-08-19       Impact factor: 3.533

8.  Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.

Authors:  Keith G Heinzerling; Aimee-Noelle Swanson; Soeun Kim; Lisa Cederblom; Ardis Moe; Walter Ling; Steven Shoptaw
Journal:  Drug Alcohol Depend       Date:  2010-01-25       Impact factor: 4.492

9.  The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

Authors:  Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2009-04-23       Impact factor: 4.492

Review 10.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.